New combo therapy aims to shrink prostate cancer before surgery
NCT ID NCT06861192
Summary
This study is testing whether adding two new drugs (fasudil hydrochloride and a PD1 inhibitor) to standard hormone therapy before prostate cancer surgery works better than standard therapy alone. The goal is to see if this combination shrinks the cancer more effectively, potentially leaving less or no cancer behind after surgery. The study will involve about 83 men with locally advanced or limited-spread prostate cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongda Hospital
RECRUITINGNanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.